SAT-198 ASC41, a selective THRβ agonist significantly reduces liver fat and ALT in biopsy-confirmed MASH patients after 12-week treatment: an interim analysis of a 52-week serial liver biopsy study

Journal of Hepatology
June 1, 2024
Cited by 1Open Access
Full Text

Abstract


Related Papers

No related papers found

Powered by citation graph analysis